Bukwang Pharmaceutical said Thursday that it has just begun domestic marketing and sales activities for Sebivo, Novartis’ hepatitis B treatment.
|Bukwang Pharmaceutical headquarters in Daebang-dong, Seoul.|
Sebivo is a chronic hepatitis B treatment regularly prescribed in the U.S., Canada, China, and the EU. The drug also received domestic sales approval from the Ministry of Food and Drug Safety in 2006.
“With the introduction of Legalon, a liver disease adjuvant, in Korea, and the development of Levovir, a new drug for chronic hepatitis B treatment, the company has shown strength in the field of liver diseases,” Bukwang said. “We have now become a company distributing nearly all of the chronic hepatitis B treatment ingredients sold in Korea with its three original products -- Levovir, Legalon, and Sebivo, as well as generic products such as Entecavir, Tenofovir, Adefovir, and Lamivudine.”
Bukwang, which has a specialized marketing and sales organization that has trained with the launch of the hepatitis B treatment market in Korea, expects that it will be able to help patients with chronic hepatitis B in the nation through the completion of this lineup.
“Sebivo is a drug that has been used for a long time by many chronic hepatitis B patients in Korea and has clinical experience in the market regarding safety and efficacy,” a company official said. “We expect that the treatment will achieve synergic effects with the company’s other liver disease treatments.”
<© Korea Biomedical Review, All rights reserved.>